![The F-35’s future: The world’s most advanced stealth fighter and what comes next [Video]](https://breakingdefense.com/wp-content/uploads/sites/3/2025/03/8477353.jpg?#)
Riding its Peloton buyout, Merck rolls to third FDA nod for potential blockbuster Welireg
Six years after Merck bought out Peloton Therapeutics, the New Jersey drugmaker is not remaining stationary with the crown jewel of the deal. The FDA has approved a third indication for Welireg, signing off on the hypoxia-inducible factor-2 alpha inhibitor to treat patients with rare pheochromocytoma or paraganglioma tumors in the endocrine system.
Six years after Merck bought out Peloton Therapeutics, the New Jersey drugmaker is not remaining stationary with the crown jewel of the deal. The FDA has approved a third indication for Welireg, signing off on the hypoxia-inducible factor-2 alpha inhibitor to treat patients with rare pheochromocytoma or paraganglioma tumors in the endocrine system.
